Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantation

BMJ Case Rep. 2012 Jul 3:2012:bcr0220125856. doi: 10.1136/bcr.02.2012.5856.

Abstract

The optimal management of patients with diffuse large B cell lymphoma relapsing after autologous haematopoetic stem cell transplantation (HCT) is difficult and no standard treatment has been defined. The authors here report the case of a rituximab-naive patient who relapsed after HCT and was cured with rituximab monotherapy.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Male
  • Middle Aged
  • Prednisone / administration & dosage
  • Recurrence
  • Remission Induction
  • Rituximab
  • Stem Cell Transplantation*
  • Vincristine / administration & dosage

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Cytarabine
  • Rituximab
  • Vincristine
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • DHAP protocol